CDXS
Codexis Inc.

2,376
Mkt Cap
$114.71M
Volume
37.1M
52W High
$3.87
52W Low
$0.9583
PE Ratio
-1.69
CDXS Fundamentals
Price
$1.71
Prev Close
$1.27
Open
$1.92
50D MA
$1.39
Beta
2.11
Avg. Volume
1.28M
EPS (Annual)
-$0.5046
P/B
2.97
Rev/Employee
$482,102.74
$136.56
Loading...
Loading...
News
all
press releases
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours?
Codexis shares jumped 37.8% in after-hours trading after the company reported a profitable fourth quarter and full-year 2025 revenue growth.read more...
Benzinga·13h ago
News Placeholder
More News
News Placeholder
Codexis (CDXS) Q4 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·20h ago
News Placeholder
Codexis Q4 Earnings Call Highlights
Codexis (NASDAQ:CDXS) used its fourth-quarter and full-year 2025 earnings call to highlight progress behind its strategic focus on RNA medicines, with management emphasizing technical milestones for...
MarketBeat·21h ago
News Placeholder
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +2,100.00% and +1.61%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·21h ago
News Placeholder
Codexis (NASDAQ:CDXS) Releases Earnings Results, Beats Expectations By $0.10 EPS
Codexis (NASDAQ:CDXS - Get Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.01 by...
MarketBeat·22h ago
News Placeholder
Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing at TD Cowen Conf
Codexis (NASDAQ:CDXS) President and CEO Alison Moore outlined the company's strategic focus on RNA medicines manufacturing at TD Cowen's 46th Annual Health Care Conference, emphasizing expected...
MarketBeat·5d ago
News Placeholder
Liquidia Corporation (LQDA) Surpasses Q4 Earnings and Revenue Estimates
Liquidia Corporation (LQDA) delivered earnings and revenue surprises of +100.00% and +19.34%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Why Did CDXS Stock Jump 7% Today?
The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.
Stocktwits·8d ago
News Placeholder
Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform
Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform PR...
PR Newswire·8d ago
News Placeholder
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of -20.67% and -99.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
<
1
2
...
>

Latest CDXS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.